Specific keynote: Molecular therapeutics in ovarian cancer

被引：15
作者：
Mills, GB
Fang, XJ
Lu, YL
Hasegawa, Y
Eder, A
Tanyi, J
Tabassam, FH
Mao, ML
Wang, HW
Cheng, KW
Nakayama, Y
Kuo, WL
Erickson, J
Gershenson, D
Kohn, EC
Jaffe, R
Bast, RC
Gray, J
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
[5] AGY Biotechnol, San Francisco, CA USA
来源：
GYNECOLOGIC ONCOLOGY | 2003年 / 88卷 / 01期
关键词：
D O I：
10.1006/gyno.2002.6692
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S88 / S92
页数：5
相关论文
共 65 条
  • [1] LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein
    Abdollahi, A
    Bao, R
    Hamilton, TC
    [J]. ONCOGENE, 1999, 18 (47) : 6477 - 6487
  • [2] Biological malignancy grading in early-stage ovarian carcinoma
    Auer, G
    Einhorn, N
    Nilsson, B
    Silfversward, C
    Sjovall, K
    [J]. ACTA ONCOLOGICA, 1996, 35 : 93 - 98
  • [3] CA 125: The past and the future
    Bast, RC
    Xu, FJ
    Yu, YH
    Barnhill, S
    Zhang, Z
    Mills, GB
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04) : 179 - 187
  • [4] Bast Robert C Jr, 2002, Cancer Treat Res, V107, P61
  • [5] Bruening W, 1999, CANCER RES, V59, P4973
  • [6] Bcr-Abl inhibition as a modality of CML therapeutics
    Buchdunger, E
    Matter, A
    Druker, BJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01): : M11 - M18
  • [7] Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
  • [8] Demirel D, 1996, CANCER, V77, P1494, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1494::AID-CNCR11>3.0.CO
  • [9] 2-V
  • [10] Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia
    Druker, B
    [J]. SEMINARS IN HEMATOLOGY, 2001, 38 (03) : 9 - 14
1234567